Enliven Therapeutics Stock Performance
| ELVN Stock | 21.08 0.16 0.76% |
The firm shows a Beta (market volatility) of 1.16, which means a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Enliven Therapeutics will likely underperform. At this point, Enliven Therapeutics has a negative expected return of -0.11%. Please make sure to confirm Enliven Therapeutics' value at risk, as well as the relationship between the daily balance of power and price action indicator , to decide if Enliven Therapeutics performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
Very Weak
Weak | Strong |
Over the last 90 days Enliven Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of latest uncertain performance, the Stock's basic indicators remain healthy and the recent disarray on Wall Street may also be a sign of long period gains for the firm investors. ...more
Actual Historical Performance (%)
One Day Return 0.76 | Five Day Return 2.28 | Year To Date Return (11.80) | Ten Year Return (64.87) | All Time Return (64.87) |
Last Split Factor 1:4 | Last Split Date 2023-02-24 |
1 | Disposition of 3350 shares by Benjamin Hohl of Enliven Therapeutics at 22.1549 subject to Rule 16b-3 | 12/27/2024 |
2 | Disposition of 900 shares by Benjamin Hohl of Enliven Therapeutics at 22.5061 subject to Rule 16b-3 | 12/30/2024 |
3 | Enliven Therapeutics Shares Up 7.6 percent Heres What Happened | 01/02/2025 |
4 | Disposition of 1000 shares by Benjamin Hohl of Enliven Therapeutics at 25.0386 subject to Rule 16b-3 | 01/03/2025 |
5 | Disposition of 1440 shares by Patel Anish of Enliven Therapeutics at 24.561 subject to Rule 16b-3 | 01/07/2025 |
6 | Disposition of 3250 shares by Benjamin Hohl of Enliven Therapeutics at 21.5932 subject to Rule 16b-3 | 01/27/2025 |
7 | Disposition of 1000 shares by Benjamin Hohl of Enliven Therapeutics at 22.5244 subject to Rule 16b-3 | 02/05/2025 |
8 | Acquisition by Collins Helen Louise of 171000 shares of Enliven Therapeutics at 22.47 subject to Rule 16b-3 | 02/06/2025 |
9 | Disposition of 6667 shares by Patel Anish of Enliven Therapeutics at 21.9298 subject to Rule 16b-3 | 02/07/2025 |
10 | Ikarian Capital, LLCs Strategic Acquisition of Traws Pharma Inc Shares | 02/14/2025 |
11 | Acquisition by Benjamin Hohl of 171000 shares of Enliven Therapeutics at 22.47 subject to Rule 16b-3 | 02/21/2025 |
12 | Enliven Therapeutics to Present at the TD Cowen 45th Annual Health Care Conference | 02/25/2025 |
13 | Disposition of 3250 shares by Benjamin Hohl of Enliven Therapeutics at 20.4083 subject to Rule 16b-3 | 02/27/2025 |
14 | Acquisition by Benjamin Hohl of 10000 shares of Enliven Therapeutics at 2.48 subject to Rule 16b-3 | 03/04/2025 |
15 | Disposition of 10420 shares by Ballal Rahul D. of Enliven Therapeutics at 28.1725 subject to Rule 16b-3 | 03/05/2025 |
16 | Disposition of 6667 shares by Patel Anish of Enliven Therapeutics at 21.4394 subject to Rule 16b-3 | 03/07/2025 |
17 | Enliven Therapeutics COO Anish Patel sells 142,936 in stock - Investing.com | 03/11/2025 |
18 | Enliven Therapeutics Stock Promising Advances in Oncology Pipeline - Value the Markets | 03/14/2025 |
19 | Disposition of 12500 shares by Kintz Samuel of Enliven Therapeutics at 20.8256 subject to Rule 16b-3 | 03/17/2025 |
20 | Disposition of 12500 shares by Joseph Lyssikatos of Enliven Therapeutics at 20.606 subject to Rule 16b-3 | 03/19/2025 |
| Begin Period Cash Flow | 100.2 M |
Enliven |
Enliven Therapeutics Relative Risk vs. Return Landscape
If you would invest 2,315 in Enliven Therapeutics on December 24, 2024 and sell it today you would lose (207.00) from holding Enliven Therapeutics or give up 8.94% of portfolio value over 90 days. Enliven Therapeutics is currently does not generate positive expected returns and assumes 3.2075% risk (volatility on return distribution) over the 90 days horizon. In different words, 28% of stocks are less volatile than Enliven, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Enliven Therapeutics Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Enliven Therapeutics' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Enliven Therapeutics, and traders can use it to determine the average amount a Enliven Therapeutics' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.0328
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | ELVN |
Estimated Market Risk
| 3.21 actual daily | 28 72% of assets are more volatile |
Expected Return
| -0.11 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.03 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Enliven Therapeutics is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Enliven Therapeutics by adding Enliven Therapeutics to a well-diversified portfolio.
Enliven Therapeutics Fundamentals Growth
Enliven Stock prices reflect investors' perceptions of the future prospects and financial health of Enliven Therapeutics, and Enliven Therapeutics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Enliven Stock performance.
| Return On Equity | -0.32 | ||||
| Return On Asset | -0.22 | ||||
| Current Valuation | 740.77 M | ||||
| Shares Outstanding | 49 M | ||||
| Price To Book | 3.33 X | ||||
| EBITDA | (104.55 M) | ||||
| Net Income | (89.02 M) | ||||
| Total Debt | 15.91 M | ||||
| Book Value Per Share | 6.33 X | ||||
| Cash Flow From Operations | (73.19 M) | ||||
| Earnings Per Share | (1.89) X | ||||
| Market Capitalization | 1.03 B | ||||
| Total Asset | 325.76 M | ||||
| Retained Earnings | (243.47 M) | ||||
| Working Capital | 302.21 M | ||||
About Enliven Therapeutics Performance
By examining Enliven Therapeutics' fundamental ratios, stakeholders can obtain critical insights into Enliven Therapeutics' financial health, operational efficiency, and overall profitability. These insights assist in making well-informed investment and management decisions. For example, a high Return on Assets and Return on Equity would indicate that Enliven Therapeutics is effectively utilizing its assets and equity to generate significant profits, enhancing its appeal to investors. On the other hand, low ROA and ROE values could reveal issues in asset and equity management, highlighting the need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.27) | (0.29) | |
| Return On Capital Employed | (0.34) | (0.35) | |
| Return On Assets | (0.27) | (0.29) | |
| Return On Equity | (0.29) | (0.27) |
Things to note about Enliven Therapeutics performance evaluation
Checking the ongoing alerts about Enliven Therapeutics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Enliven Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Enliven Therapeutics generated a negative expected return over the last 90 days | |
| Enliven Therapeutics has high historical volatility and very poor performance | |
| Net Loss for the year was (89.02 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Enliven Therapeutics generates negative cash flow from operations | |
| Enliven Therapeutics has a frail financial position based on the latest SEC disclosures | |
| Over 94.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from news.google.com: Disposition of 12500 shares by Joseph Lyssikatos of Enliven Therapeutics at 20.606 subject to Rule 16b-3 |
- Analyzing Enliven Therapeutics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Enliven Therapeutics' stock is overvalued or undervalued compared to its peers.
- Examining Enliven Therapeutics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Enliven Therapeutics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Enliven Therapeutics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Enliven Therapeutics' stock. These opinions can provide insight into Enliven Therapeutics' potential for growth and whether the stock is currently undervalued or overvalued.
Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Enliven Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in real. To learn how to invest in Enliven Stock, please use our How to Invest in Enliven Therapeutics guide.You can also try the Share Portfolio module to track or share privately all of your investments from the convenience of any device.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Enliven Therapeutics. If investors know Enliven will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Enliven Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Enliven Therapeutics is measured differently than its book value, which is the value of Enliven that is recorded on the company's balance sheet. Investors also form their own opinion of Enliven Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Enliven Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Enliven Therapeutics' market value can be influenced by many factors that don't directly affect Enliven Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Enliven Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Enliven Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Enliven Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.